Search Results for: c

ACTUATE THERAPEUTICS ANNOUNCES 9-ING-41 DATA PRESENTATION AT ASCO ANNUAL MEETING 2020

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today that interim results from their 1801 Phase 1/2 study (NCT03678883, EudraCT #: 2018-003739-32) will be presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting which will take place virtually on May 29th, 2020. Dr. […]

ACTUATE THERAPEUTICS ANNOUNCES 9-ING-41 DATA PRESENTATION AT ASCO ANNUAL MEETING 2020 Read More »

ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF ADDITIONAL CLINICAL STUDIES FOR 9-ING-41

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced the initiation of two additional clinical studies with its lead molecule, 9-ING-41, a Glycogen Synthase Kinase beta (GSK-3β) inhibitor. On April 8, the company opened its 1902 study: A Phase 1 study of 9-ING-41, a Glycogen Synthase

ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF ADDITIONAL CLINICAL STUDIES FOR 9-ING-41 Read More »

ACTUATE THERAPEUTICS COMPLETES $6.5 MILLION SERIES B-3 FINANCING TO EXPAND CLINICAL PROGRAMS

CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced it has raised an additional $6.5M in a Series B-3 financing round. This Series B-3 was led by Bios Partners with Kairos Ventures, DEFTA Partners, and other existing investors participating, and brings total funding for Actuate’s Series B

ACTUATE THERAPEUTICS COMPLETES $6.5 MILLION SERIES B-3 FINANCING TO EXPAND CLINICAL PROGRAMS Read More »